BI 655064
As of the edition of 20 October 2026, BI 655064 is a drug known only by a code name: went quiet in 2021; acts on CD40.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2021
- Kind
- Code name only
- Registered trials
- 7, 1 stopped early
- Disease areas
- Immune system; Skin and connective tissue; Pregnancy and women's health; Urinary and reproductive; Blood and lymph; Bones, joints and muscles
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of BI 655064.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD40 | Tumor necrosis factor receptor superfamily member 5 | P25942 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 4 | 0 | 1 |
| Phase 2 | 2 | 2 | 0 | 0 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Boehringer Ingelheim | Lead sponsor of trials | 2012 to now |